CN107333750A - Blood cell stabilizer when a kind of long - Google Patents
Blood cell stabilizer when a kind of long Download PDFInfo
- Publication number
- CN107333750A CN107333750A CN201710435413.6A CN201710435413A CN107333750A CN 107333750 A CN107333750 A CN 107333750A CN 201710435413 A CN201710435413 A CN 201710435413A CN 107333750 A CN107333750 A CN 107333750A
- Authority
- CN
- China
- Prior art keywords
- stabilizer
- blood
- potassium bichromate
- blood cell
- long
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Physiology (AREA)
- Engineering & Computer Science (AREA)
- Dentistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides it is a kind of long when blood cell stabilizer, the stabilizer is composed of the following components：80 ~ 200 μm of 20 ~ 40 μm of ol/L of disodium Cromoglycic acid, the mg/L of poloxamer 0.12 ~ 0.16,120 ~ 140 μm of beta cyclodextrin 10 ~ 12 μm of ol/L, Yi Keduoyin ol/L, 20 ~ 25 μm of ol/L of Triflusal, potassium bichromate 0.07%, trehalose ol/L, the potassium bichromate is mass percent concentration.The blood cell stabilizer of gained of the invention can be in very effective stable blood haemocyte and prevent platelet aggregation, the stablizing effect of at least 120 hours can be provided for haemocyte, for existing product, at least extend the stabilization time of 48 hours.
Description
Technical field
The invention belongs to cell technology field, and in particular to blood cell stabilizer when a kind of long.
Background technology
In the blood research of correlation and clinical research, the stabilization of blood cell is very important.In general, collection
After whole blood, common blood anticoagulant can only provide the blood stablizing effect within 6 hours.As reagent is replaced, formaldehyde is solid
Determine agent（Such as Kryofix）Also be often used, but formaldehyde has toxicity and is easy to volatilize, exist certain quality control difficulty and
Potential safety hazard.
In recent years, occur some new blood cell stabilizers successively, it mainly passes through beta-schardinger dextrin, disodium color
Sweet acid and potassium bichromate carry out stabilizing cell membrane, on this basis, are further provided for by adding EDTA tri- plus salt or adenosine
The stablizing effect of blood.But, existing stabilizer can be provided stabilization time or very limited, what is be currently known is most normal
Time is only 72 hours.
In disaster medical rescue or in the medical assistance work of remote districts, the stationary phase of 72 hours is often
It is inadequate.In addition, in some time-consuming very long blood tests, due to needing blood source consistent, common stabilizer is difficult to provide
So long stabilization time, corresponding experiment is caused to be difficult to carry out.
The content of the invention
For blood cell stabilizer can be provided in the prior art stationary phase it is shorter the shortcomings that, the purpose of the present invention it
One blood cell stabilizer when being to provide a kind of long, the stabilizer are composed of the following components：
20 ~ 40 μm of ol/L of disodium Cromoglycic acid
The mg/L of poloxamer 0.12 ~ 0.16
120 ~ 140 μm of ol/L of beta-schardinger dextrin
10 ~ 12 μm of ol/L of Yi Keduoyin
20 ~ 25 μm of ol/L of Triflusal
Potassium bichromate 0.07%
80 ~ 200 μm of ol/L of trehalose
The potassium bichromate is mass percent concentration.
As preferable scheme, the stabilizer is composed of the following components：
25 μm of ol/L of disodium Cromoglycic acid
The mg/L of poloxamer 0.13
125 μm of ol/L of beta-schardinger dextrin
11.5 μm of ol/L of Yi Keduoyin
23 μm of ol/L of Triflusal
Potassium bichromate 0.07%
160 μm of ol/L of trehalose
The potassium bichromate is mass percent concentration.
Another object of the present invention is in the application in the above-mentioned blood cell stabilizer of offer in blood is stablized.
In terms of existing technologies, advantage for present invention is：
The blood cell stabilizer of gained of the invention can be in very effective stable blood haemocyte and prevent platelet aggregation,
The stablizing effect of at least 120 hours can be provided for haemocyte, for existing product, at least extended 48 hours
Stabilization time.
Embodiment
The present invention is specifically described below by embodiment, it is necessary to it is pointed out here that be following examples simply use
It is further detailed in the present invention, it is impossible to be interpreted as limiting the scope of the invention, the field is skilled in technique
Some nonessential modifications and adaptations that personnel are made according to foregoing invention content, still fall within protection scope of the present invention.
Embodiment 1
By following concentration, each component raw material is weighed, is dissolved in aseptic deionized water, and constant volume.
25 μm of ol/L of disodium Cromoglycic acid
The mg/L of poloxamer 0.13
125 μm of ol/L of beta-schardinger dextrin
11.5 μm of ol/L of Yi Keduoyin
23 μm of ol/L of Triflusal
Potassium bichromate 0.07%
160 μm of ol/L of trehalose
The potassium bichromate is mass percent concentration.
Embodiment 2
By following concentration, each component raw material is weighed, is dissolved in aseptic deionized water, and constant volume.
20 μm of ol/L of disodium Cromoglycic acid
The mg/L of poloxamer 0.12
120 μm of ol/L of beta-schardinger dextrin
10 μm of ol/L of Yi Keduoyin
20 μm of ol/L of Triflusal
Potassium bichromate 0.07%
80 μm of ol/L of trehalose
The potassium bichromate is mass percent concentration.
Embodiment 3
By following concentration, each component raw material is weighed, is dissolved in aseptic deionized water, and constant volume.
40 μm of ol/L of disodium Cromoglycic acid
The mg/L of poloxamer 0.16
140 μm of ol/L of beta-schardinger dextrin
12 μm of ol/L of Yi Keduoyin
25 μm of ol/L of Triflusal
Potassium bichromate 0.07%
200 μm of ol/L of trehalose
The potassium bichromate is mass percent concentration.
Reference examples 1
Except the concentration of disodium Cromoglycic acid is 18 μm of ol/L, outside Yi Keduoyin concentration is 15 μm of ol/L, remaining and embodiment 1
Unanimously.
Reference examples 2
Except trehalose being replaced with into PEG1000 and concentration is 1.25 mmol/L, Yi Keduoyin concentration for 15 μm of ol/L it
Outside, remaining is consistent with embodiment 1.
Reference examples 3
The gained stabilizer of embodiment 6 in Chinese patent 201410784318.3.
Reference examples
The gained stabilizer of embodiment 1 in Chinese patent 201410534999.8.
The gained stabilizer of embodiment 1 ~ 3 is added in whole blood blood sample, after standard preserves 120 hours, taken out, naked-eye observation,
It is consistent before the color of whole blood blood sample and preservation, take on a red color, blood sample is without condensation phenomenon.The gained stabilizer of reference examples 1 ~ 4 is added complete
In blood blood sample, after standard preserves 120 hours, take out, naked-eye observation, whole blood blood sample occurs to condense in various degree, and color is thin out, is in
Pale red.Illustrate the blood cell stabilizer using the present invention, after the preservation of 120 hours, the cell in blood is still
Stable.
Claims (3)
1. blood cell stabilizer when a kind of long, it is characterised in that the stabilizer, it is composed of the following components：
20 ~ 40 μm of ol/L of disodium Cromoglycic acid
The mg/L of poloxamer 0.12 ~ 0.16
120 ~ 140 μm of ol/L of beta-schardinger dextrin
10 ~ 12 μm of ol/L of Yi Keduoyin
20 ~ 25 μm of ol/L of Triflusal
Potassium bichromate 0.07%
80 ~ 200 μm of ol/L of trehalose
The potassium bichromate is mass percent concentration.
2. stabilizer according to claim 1, it is characterised in that the stabilizer, it is composed of the following components：
25 μm of ol/L of disodium Cromoglycic acid
The mg/L of poloxamer 0.13
125 μm of ol/L of beta-schardinger dextrin
11.5 μm of ol/L of Yi Keduoyin
23 μm of ol/L of Triflusal
Potassium bichromate 0.07%
160 μm of ol/L of trehalose
The potassium bichromate is mass percent concentration.
3. application of the stabilizer of claim 1 or 2 in blood is stablized.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710435413.6A CN107333750A (en) | 2017-06-11 | 2017-06-11 | Blood cell stabilizer when a kind of long |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710435413.6A CN107333750A (en) | 2017-06-11 | 2017-06-11 | Blood cell stabilizer when a kind of long |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107333750A true CN107333750A (en) | 2017-11-10 |
Family
ID=60220365
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710435413.6A Pending CN107333750A (en) | 2017-06-11 | 2017-06-11 | Blood cell stabilizer when a kind of long |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107333750A (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0677044A1 (en) * | 1992-12-31 | 1995-10-18 | GALINSKI, Erwin, A. | $i(IN VIVO) METHOD OF OBTAINING CELL COMPONENTS |
| CN1179107A (en) * | 1995-01-19 | 1998-04-15 | 廓德伦特控股剑桥有限公司 | Dried blood factor composition comprising trehalose |
| CN1683522A (en) * | 2005-03-04 | 2005-10-19 | 江西特康科技有限公司 | Whole blood quality control substance as cell bio-activity protector and its preparing method |
| WO2010025859A2 (en) * | 2008-08-26 | 2010-03-11 | Universität Rostock | Stabilization of cells by ionic liquids |
| CN104381245A (en) * | 2014-10-13 | 2015-03-04 | 邓杏飞 | Reagent for stabilization of blood sample cells |
| CN104634628A (en) * | 2014-12-16 | 2015-05-20 | 邓杏飞 | Blood stabilizer and application thereof |
| CN105121629A (en) * | 2013-03-15 | 2015-12-02 | 特拉基应用基因组学有限责任公司 | Cell culture compositions with antioxidants and methods for polypeptide production |
| CN105961374A (en) * | 2016-07-04 | 2016-09-28 | 深圳市合康生物科技股份有限公司 | Cell cryopreservation fluid |
-
2017
- 2017-06-11 CN CN201710435413.6A patent/CN107333750A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0677044A1 (en) * | 1992-12-31 | 1995-10-18 | GALINSKI, Erwin, A. | $i(IN VIVO) METHOD OF OBTAINING CELL COMPONENTS |
| CN1179107A (en) * | 1995-01-19 | 1998-04-15 | 廓德伦特控股剑桥有限公司 | Dried blood factor composition comprising trehalose |
| CN1683522A (en) * | 2005-03-04 | 2005-10-19 | 江西特康科技有限公司 | Whole blood quality control substance as cell bio-activity protector and its preparing method |
| WO2010025859A2 (en) * | 2008-08-26 | 2010-03-11 | Universität Rostock | Stabilization of cells by ionic liquids |
| CN105121629A (en) * | 2013-03-15 | 2015-12-02 | 特拉基应用基因组学有限责任公司 | Cell culture compositions with antioxidants and methods for polypeptide production |
| CN104381245A (en) * | 2014-10-13 | 2015-03-04 | 邓杏飞 | Reagent for stabilization of blood sample cells |
| CN104634628A (en) * | 2014-12-16 | 2015-05-20 | 邓杏飞 | Blood stabilizer and application thereof |
| CN105961374A (en) * | 2016-07-04 | 2016-09-28 | 深圳市合康生物科技股份有限公司 | Cell cryopreservation fluid |
Non-Patent Citations (3)
| Title |
|---|
| 周雪艳 等: "抗凝剂及稳定剂在实验室的应用", 《国外医学临床生物化学与检验学分册》 * |
| 张敬慧: "《酿酒微生物》", 31 January 2015, 中国轻工业出版社 * |
| 肖丽蓉 等: "海藻糖的研究与应用", 《中国蚕业》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017015304A (en) | Cannabis plants having modified expression of thca synthase. | |
| Xie et al. | The effect of platelet‐derived microparticles in stored apheresis platelet concentrates on polymorphonuclear leucocyte respiratory burst | |
| Carvalho et al. | Control of osmotic pressure to improve cell viability in cell‐laden tissue engineering constructs | |
| Nogawa et al. | Parallel comparison of apheresis‐collected platelet concentrates stored in four different additive solutions | |
| BR112017019774A2 (en) | use of a porous capillary membrane to determine the amount of rolling circle amplification products | |
| Noulsri et al. | Effects of donor age, donor sex, blood-component processing, and storage on cell-derived microparticle concentrations in routine blood-component preparation | |
| Zhang et al. | Excess manganese-induced apoptosis in chicken cerebrums and embryonic neurocytes | |
| Luz-Veiga et al. | Cannabidiol and cannabigerol exert antimicrobial activity without compromising skin microbiota | |
| WO2015123192A3 (en) | Universal system, method and solution for the acceleration of the process of fixing, dehydrating and clearing the structure of biological tissue | |
| Cekauskas et al. | Sulforaphane decreases kidney injury after transplantation in rats: role of mitochondrial damage. | |
| Leitner et al. | Altered intracellular purine nucleotides in gamma‐irradiated red blood cell concentrates | |
| CN107333750A (en) | Blood cell stabilizer when a kind of long | |
| FR2977630B1 (en) | METHOD FOR SAMPLING POLYMER-BASED SOLUTIONS USED IN UNDERGROUND FORMATIONS | |
| PL403996A1 (en) | Method for simultaneous detection of bacteria and fungi in a biological preparation by PCR primers and a set for the detection of bacteria and fungi | |
| CN106472483A (en) | A kind of liquid based cell preservative fluid and preparation method thereof | |
| Castrillo et al. | In vitro evaluation of platelet concentrates suspended in additive solution and treated for pathogen reduction: effects of clumping formation | |
| ES2909392T3 (en) | Method and composition for the stabilization of cell-free and cell-free nucleic acids | |
| Xu et al. | Vitamin D analog EB1089 could repair the defective bone marrow-derived mesenchymal stromal cells in patients with systemic lupus erythematosus | |
| Kelly et al. | Hyperbaric treatment of platelets extends in vitro storage to 14 days | |
| Radwanski et al. | Cryopreserved ECP‐treated lymphocytes maintain apoptotic response and anti‐proliferative effect | |
| BR112018006452A2 (en) | aqueous dispersion | |
| Choi et al. | Hemorrhagic enteritis in two one-month-old dairy calves infected with beta2-toxigenic Clostridium perfringens and Coccidium. | |
| Mal'chevskiĭ | Character of changes in the rheological parameters of blood in patients with heart failure III-IV FC treated by the combination therapy with plasmapheresis | |
| Khajanchi et al. | Indians fit the Asian trauma model | |
| Johnson et al. | A deep eutectic solvent is an effective cryoprotective agent for platelets. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171110 |
|
| RJ01 | Rejection of invention patent application after publication |